ANGOAngioDynamics, Inc.
Is the price fair?
Priced for +46% a year vs −1% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~46% a year FCF growth. The price already bakes in strong, sustained growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ANGO's price assumes
AngioDynamics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.08× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.28%
Free cash flow yield · Medical Instruments & Supplies median 3.6%
- Growth the price implies
- +46%
Growth the price implies · The price pays for +46% free cash flow growth a year for a decade; revenue has shrunk 1.1% a year over the last three.
- Price / book
- 4.13
Price / book · as of 2026-Q3
Details›
- Price / bookas of 2026-Q3
- 4.13
- EV / EBIToperating margin −11%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $1.4M
- Market capitalisation42.1 million shares, counted Oct 7, 2026
- $520M
- 3-year revenue growth
- −1.1%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Medical Instruments & Supplies
Ranks #19 of 20 by RyuScore